GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Glaxosmithkline's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, GlaxoSmithKline (GSK) reported global carbon emissions of approximately 521,000,000 kg CO2e for Scope 1 and 44,000,000 kg CO2e for Scope 2, totalling about 565,000,000 kg CO2e for both scopes combined. In the UK, GSK's Scope 1 and 2 emissions were reported at approximately 92,000,000 kg CO2e. In 2023, GSK's global emissions included 581,000,000 kg CO2e for Scope 1, 64,000,000 kg CO2e for Scope 2, and a significant 8,983,000,000 kg CO2e for Scope 3 emissions. GSK has set ambitious climate commitments, aiming for net zero emissions across all operations (Scope 1 and 2) by 2030 and across its full value chain (all scopes) by 2045. The company has committed to reducing absolute Scope 1 and 2 emissions by 80% by 2030 and by 90% by 2045, using a 2020 baseline. Additionally, GSK aims to reduce Scope 3 emissions by 80% by 2030 and 90% by 2045. In 2021, GSK achieved a 15% reduction in Scope 1 and 2 emissions compared to 2020. The company is also aligned with the Science Based Targets initiative (SBTi), committing to a 34% reduction in absolute Scope 1 and 2 emissions by 2025 from a 2017 baseline, and a 16% reduction in Scope 3 emissions by 2030 from the same baseline. GSK's climate strategy includes investments in high-quality nature-based solutions to offset remaining emissions, reinforcing its commitment to sustainability and environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 430,000 | 000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.